Uwe Platzbecker, MD, discusses the FDA approval of luspatercept for the treatment of anemia in patients who have not had prior treatment with erythropoiesis-stimulating agent and may require regular red blood cell transfusions could change the sequencing of agents for this patient population.
Longer follow-up data for 1-year transfusion independence in IMerge Phase 3, which demonstrated statistically significant and clinically meaningful continuous, durable efficacy
Strong. | May 11, 2023
Longer follow-up data for 1-year transfusion independence (TI) in IMerge Phase 3, which demonstrated statistically significant and clinically meaningful continuous, durable efficacy Strong